Overview
ANTENGENE-B (6996)
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The comp...
- Open
- 2.900
- High
- 2.900
- Low
- 2.525
- Prev. Close
- 2.710
- Volume
- 980.50K
- Turnover
- 2.54M
- Avg Price
- 2.586
- Bid/Ask Ratio
- -95.24%
- Amplitude
- 13.84%
- 52wk High
- 6.280
- Volume Ratio
- 0.57
- Turnover Ratio
- 0.14%
- 52wk Low
- 2.525
- HK Mkt Cap
- 1.77B
- Market CapHKD
- 1.77B
- P/ETTM
- 28.74
- P/EDynamic
- 3.56
- P/EStatic
- --
- EPSTTM
- 0.0903
- EPSDynamic
- 0.729
- EPSStatic
- --
- BVPS
- 1.54
- P/B
- 1.69
- HK Shares
- 683.32M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 683.32M
- Min lot size
- 500
- Currency
- HKD
ANTENGENE-B Analyst Rating
View moreForecast & Rating
Aug 27, 2026- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 0
- Buy
- 0
- Hold
- 1
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Antengene opened at HK$2.900 and faded through the day to close HK$2.595, down 4.24% from HK$2.710 on 980,500 shares worth HK$2.54 million, a thin 0.14% turnover; the morning slipped from 2.650 to 2.560 and the afternoon probed 2.535, a spike-and-fade pattern whose main cause was scarce follow-through buying after the prior session's 52-week low of 2.525, with SITC preclinical readouts on ATG-109 and AnTenGager-D2, ATG-207 data and first dosing of ATG-201 already absorbed by an earlier 6% bounce. Fundamentals diverge from the tape: Q2 2026 revenue reached HK$296.3 million, up 916.9% yoy, net profit HK$124.9 million, up 398.6%, net margin 42.17% and EPS HK$0.1964, yet the price sits below MA20 of 2.826 and MA60 of 3.252, down 33.63% YTD and 58.68% below the 52-week high of 6.28, at 28.7x PE and 1.69x PB. Buybacks have continued, though the stock is only 2.77% above its 52-week low.
- Nov, 13
Antengene (6996.HK) spiked and faded, opening at HK$2.950 for the session high before sliding to a HK$2.645 low in the afternoon session and closing at HK$2.710, down 3.90% from HK$2.820, on thin 503,500 shares and HK$1.36 million turnover. Q2 2026 revenue of HK$296.3 million (+916.94% yoy), net profit of HK$124.9 million (+398.58%) and a 42.17% net margin sit against PE 30.02x and PB 1.76x, yet the stock is down 30.69% year-to-date, 56.85% below its April 14 52-week high of HK$6.28 and only 3.44% above the November 2 low of HK$2.62, trading under both MA20 (2.85) and MA60 (3.276). Neither the 46.7% response rate for ATG-022 in Phase II gastric cancer, first patient dosing of ATG-201, the SITC 2026 AnTenGager-D2 data nor repeated buyback disclosures reversed the drift, though the buybacks and steady data flow offer some support.
- Nov, 10
Antengene rose 4.6% to HK$2.82 as the company used SITC 2026 to release three updates in quick succession: ATG-109 outperforming a clinical benchmark in a preclinical prostate cancer model, the AnTenGager-D2 Cos-TCE platform selected for a rapid oral abstract, and first patient dosing in the Phase I ATTRACT study of ATG-201 (CD19 x CD3 TCE) for B cell-mediated autoimmune diseases. The session traced a gap-up then fade: an open at HK$2.905, a morning peak of HK$2.86 at 10:47, a slide to HK$2.76, then afternoon consolidation between HK$2.80 and HK$2.84 on 391,500 shares. The tension sits between fundamentals and price: Q2 2026 revenue of HK$296.3 million (+916.9% yoy), net profit of HK$124.9 million (+398.6%) and EPS of HK$0.1964 (+391%) contrast with a close still below the MA20 of HK$2.876 and MA60 of HK$3.333, a 27.9% YTD decline and a 55.1% gap to the April 14 high of HK$6.28. Though these readouts remain early-stage, with turnover at just 0.06%.
- Nov, 6
Antengene fell 4.4% to HK$2.82 from a HK$2.95 previous close in a spike-and-fade session, opening at HK$2.89 and printing the day's high of HK$2.935 in the first minutes before sliding to HK$2.725 by 14:48 BJ and settling near HK$2.755 into the 16:00 close, with successive buybacks (78,000 shares on Nov 3, 108,000 on Nov 2) failing to hold the bid and news of the first patient dosed in the Phase I ATTRACT study of ATG-201 (CD19 x CD3 TCE) doing little for sentiment. That sits against the fundamentals: Q2 2026 revenue of HK$296.3m, up 916.9% yoy, net profit HK$124.9m, a 42.2% net margin and EPS of HK$0.1964, while the stock is down 27.9% YTD, 55.1% below its 52-week high of HK$6.28 and still under the MA20 of HK$2.913 and MA60 of HK$3.392. Though the price remains only 7.6% above the Nov 2 52-week low of HK$2.62, on turnover of 0.05%.
- Nov, 5
Antengene-B closed up 5.0% at HK$2.95, extending its rebound from the 52-week low of HK$2.62 set on November 2, as a run of near-daily buybacks and residual interest in ATG-022's 46.7% objective response rate in a Phase II gastric cancer trial lifted the stock to an intraday peak of HK$2.985 in the morning session, before it slipped to HK$2.90 at the 13:00 afternoon open and recovered into the close; turnover was 553,500 shares worth HK$1.62 million. Fundamentals diverge sharply from the tape: Q2 2026 revenue reached HK$296.3 million, up 916.94% year on year, with net profit of HK$124.9 million, a 42.17% net margin and EPS of HK$0.1964, yet the shares remain down 24.55% year to date, 53.03% below the April 14 high of HK$6.28 and under the MA60 of HK$3.421, holding only just above the MA20 of HK$2.937. The company repurchased 108,000 shares on November 2 and 78,000 on November 3 for HK$303,600 and HK$210,300. Though a 0.08% turnover rate and HK$2.02 billion market value suggest the bounce lacks fresh volume.
News
PUBT · Antengene Files Next-Day Disclosure Return to HKEX Announcing Share Buyback
Market Movers · Antengene drops 6% in Hong Kong trading
PUBT · Antengene Files Next-Day Disclosure Return With HKEX Announcing Share Buyback
PUBT · Antengene Reports ATG-207 Efficacy in Preclinical Autoimmune Disease Models
PUBT · Antengene Reports Share Buyback in Next-Day Disclosure to HKEX
